Skip to main content
. Author manuscript; available in PMC: 2011 Apr 29.
Published in final edited form as: Cancer Res. 2009 May 12;69(10):4309–4318. doi: 10.1158/0008-5472.CAN-08-4102

Figure 1.

Figure 1

Tolerance to GVAX in tumor-bearing ProHA × TRAMP mice. A, expression of HA by transfected TRAMP-C2 cells. Dotted line, isotype control. B, immunogenicity of T-GVAX. TRAMP-C2-HA cells were admixed with GM-CSF–secreting bystanders (T-GVAX) and administered intradermally 2 d after adoptive transfer of CFSE-labeled, HA-specific CD8+ T Cells. Peripheral blood cells from tail vein were harvested on indicated days postimmunization. Data are gated on HA-specific CD8+ Thy1.1+ lymphocytes that divided at least once. Mean ± SE. Three animals per group, representative of two experiments. C, T-GVAX-mediated proliferation. As above, CFSE plots gated on clonotypic (CD8+ Thy1.1+) T cells. D, tolerance to T-GVAX in tumor-bearing mice. CFSE-labeled HA-specific CD8+ T cells were adoptively transferred to indicated mice, and animals were treated 2 d posttransfer with T-GVAX immunotherapy. Seven days posttreatment, splenocytes were harvested and counted, and IFN-γ was quantified by intracellular staining. Three animals per group, representative of two experiments.